Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Opko Health Inc. (NASDAQ:OPK) by 136.7% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 498,896 shares of the biotechnology company’s stock after purchasing an additional 288,114 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Opko Health were worth $1,726,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Meeder Asset Management Inc. lifted its holdings in shares of Opko Health by 1,290.1% in the 3rd quarter. Meeder Asset Management Inc. now owns 31,611 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 29,337 shares during the period. SG Americas Securities LLC acquired a new position in shares of Opko Health in the 2nd quarter valued at about $136,000. RPg Family Wealth Advisory LLC lifted its holdings in shares of Opko Health by 74.3% in the 2nd quarter. RPg Family Wealth Advisory LLC now owns 31,080 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 13,250 shares during the period. AMS Capital Ltda acquired a new position in shares of Opko Health in the 3rd quarter valued at about $209,000. Finally, Montag A & Associates Inc. acquired a new position in shares of Opko Health in the 3rd quarter valued at about $236,000. Hedge funds and other institutional investors own 26.20% of the company’s stock.

Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Opko Health from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a report on Friday, November 30th. Barrington Research reissued a “buy” rating and issued a $7.00 price objective on shares of Opko Health in a report on Monday, November 12th. BidaskClub cut Opko Health from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 8th. Finally, ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a report on Friday, September 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Opko Health currently has a consensus rating of “Buy” and an average target price of $9.50.

NASDAQ OPK opened at $3.25 on Friday. The stock has a market capitalization of $1.95 billion, a P/E ratio of -11.07 and a beta of 1.90. Opko Health Inc. has a twelve month low of $2.66 and a twelve month high of $6.40. The company has a quick ratio of 0.78, a current ratio of 0.91 and a debt-to-equity ratio of 0.03.

Opko Health (NASDAQ:OPK) last released its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $250.00 million during the quarter, compared to analysts’ expectations of $264.04 million. Opko Health had a negative return on equity of 8.68% and a negative net margin of 30.24%. Opko Health’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.08) EPS. As a group, equities research analysts expect that Opko Health Inc. will post -0.21 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Opko Health Inc. (OPK) Shares Bought by Connor Clark & Lunn Investment Management Ltd.” was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/12/07/opko-health-inc-opk-shares-bought-by-connor-clark-lunn-investment-management-ltd.html.

Opko Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Recommended Story: Fundamental Analysis – How It Helps Investors

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.